Neptune Technologies

  • Long-Term Growth With Biotech Innovators

    By Madhukar Dubey - July 31, 2013 | Tickers: ACRX, NEPT, SRPT

    The global biotechnology industry is expected to reach $320 billion by 2015, up from $232 billion in 2012. Improving healthcare infrastructure and focus on research and development is driving industry growth. The companies in this industry are developing new drugs and performing clinical trials for FDA approval. This article analyzes three biotech companie which are small in terms of market cap. With new products and continuous efforts for product development more »

  • Reasons to Buy This Pharmaceutical Company

    By Mohsin Saeed - February 11, 2013 | Tickers: AMRN, GSK, NEPT

    The small pharmaceutical companies have a number of weaknesses when compared to big pharmaceuticals. While they usually have competent management that can effectively oversee the development of a drug candidate, it is extremely rare that they also possess the resources to effectively market their own product. This is the very reason small pharmaceuticals are such attractive acquisition plays. If a company has managed to develop an interesting candidate it is more »